GLP-1s and Mast Cell Activation: What If You Also Have POTS?

I get some version of this question a lot: "I heard that a GLP-1 might help my mast cells, but I also have POTS — won't that make my heart rate and blood pressure worse?"

It's a fair worry. If you're living with hypermobile EDS, MCAS, and dysautonomia together — which is an incredibly common combination, not a coincidence — you've probably learned to be suspicious of any medication that touches your autonomic nervous system. I've had my own body teach me that lesson more than once. So let's actually walk through what the evidence says, because the honest answer is "it's more nuanced than a yes or no."

The mast cell piece: this is actually encouraging news

The first real evidence here comes from a 2025 case series by Afrin and colleagues — the first published look at GLP-1 receptor agonists specifically in refractory MCAS. Of 47 patients treated with various GLP-1 RAs, 89% saw clinical benefit across a range of MCAS-related symptoms.Why would a diabetes and weight-loss drug help mast cells behave? The mechanism is plausible and grounded in basic receptor biology: the GLP-1 receptor is a Gαs-coupled receptor, meaning activating it raises intracellular cAMP. cAMP is a well-established "calm down" signal for mast cells — receptors that raise it tend to suppress degranulation, while receptors that lower it tend to provoke it. So the working theory is that GLP-1 receptor activation on mast cells directly stabilizes them, on top of whatever broader anti-inflammatory effects these drugs have throughout the body.That's a genuinely exciting early finding. It's also, I want to be clear, one case series — not a randomized trial, and it didn't report outcomes broken out by which specific GLP-1 RA people were on. This is a class-level signal, not proof for any one drug, and using a GLP-1 RA for MCAS is an off-label use built on emerging evidence.

The dysautonomia piece: this is where it gets more complicated

Here's the tension. GLP-1 receptor agonists as a class are known to increase heart rate — typically a modest 2–4 bpm bump — and lower blood pressure. For someone without orthostatic issues, that's usually a non-event. For someone with POTS or another form of dysautonomia, a drug that nudges heart rate up and blood pressure down is touching the exact two dials you're already fighting with.Comparing the two most-used agents:Heart rate: Roughly similar between semaglutide and tirzepatide at typical doses. At the highest tirzepatide dose (15 mg), though, there's a clearer dose-dependent increase, and preclinical work has shown tirzepatide specifically driving greater sympathetic nervous system activation than GLP-1 RAs as a class — this is dual GIP + GLP-1 receptor agonism potentially having an additive effect on the sympathetic system. Worth flagging: this specific mechanistic data comes from animal studies, not humans, so it's a reason for caution rather than a settled fact.Blood pressure: Tirzepatide lowers systolic blood pressure somewhat more than semaglutide (roughly 5–6.5 mmHg vs. 3.6–4.8 mmHg across trials). For someone whose issue is blood pooling and orthostatic drops, that's the more relevant number, and it points toward semaglutide as the gentler option.GI effects: Both drugs slow gastric emptying and can cause nausea, and semaglutide's nausea/vomiting rates run a bit higher in trials. This matters for dysautonomia specifically because dehydration from GI upset can itself worsen orthostatic symptoms — a side effect that indirectly feeds right back into the problem you're trying to solve.Put together: semaglutide looks like it may have a modest theoretical edge for people with dysautonomia, mainly because of the smaller blood pressure drop and lower sympathetic activation profile. Neither drug has actually been studied in people with dysautonomia. Everything above is extrapolated from diabetes and obesity trials in the general population alongside anecdotal reports. 

What this means practically

If you and your provider decide a GLP-1 RA is worth trying for MCAS despite comorbid POTS, the reasonable approach — based on how these mechanisms interact rather than on any dysautonomia-specific trial — looks like:Start at the lowest available dose, and titrate slower than the standard scheduleTrack orthostatic vitals (lying/standing heart rate and blood pressure) through initiation and each dose increaseStay ahead of hydration and electrolytes, since GI side effects can compound orthostatic symptomsTreat this as an experimental process, not a guaranteed fix

Where I land

This isn't a situation with a clean answer, and I'd be doing you a disservice if I pretended otherwise. What I can tell you is that the mast cell data is a real, if early, reason for optimism, and that if a GLP-1 RA is on the table for you, the conversation about which one and how slowly matters more than most people realize going in.This is exactly the kind of intersection — hypermobility, mast cells, and the autonomic nervous system, layered onto midlife hormones — that most standard menopause or MCAS resources don't touch. If that's the terrain you're navigating, join the Bendy Menopause newsletter for more of this kind of deep-dive, and get on the waitlist for The BENDY Method — a 12-week program built specifically for bodies with hypermobility, MCAS, and POTS in mind.  

References

1. Afrin LB, Weinstock LB, Dempsey TT, et al. Utility of Glucagon-Like-Peptide-1-Receptor Agonists in Mast Cell Activation Syndrome. The American Journal of the Medical Sciences. 2025. doi:10.1016/j.amjms.2025.07.006

2. Lymperopoulos A, Borges JI, Stoicovy RA. Cyclic Adenosine Monophosphate in Cardiac and Sympathoadrenal GLP-1 Receptor Signaling: Focus on Anti-Inflammatory Effects. Pharmaceutics. 2024;16(6):693. doi:10.3390/pharmaceutics16060693

3. Halova I, Rönnberg E, Draberova L, et al. Changing the Threshold—Signals and Mechanisms of Mast Cell Priming. Immunological Reviews. 2018;282(1):73-86. doi:10.1111/imr.12625

4. Frías JP, Davies MJ, Rosenstock J, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. The New England Journal of Medicine. 2021;385(6):503-515. doi:10.1056/NEJMoa2107519

5. Yang Y, He L, Liu P, et al. Impact of a Dual GIP/GLP-1 Receptor Agonist Tirzepatide on Heart Rate Among Patients with Type 2 Diabetes: A Systematic Review and Network Meta-Analysis. Diabetes, Obesity & Metabolism. 2024;26(2):548-556. doi:10.1111/dom.15342

6. Aroda VR, Erhan U, Jelnes P, et al. Safety and Tolerability of Semaglutide Across the SUSTAIN and PIONEER Phase IIIa Clinical Trial Programmes. Diabetes, Obesity & Metabolism. 2023;25(5):1385-1397. doi:10.1111/dom.14990

7. Ono Y, Shinohara K, Nakashima H, et al. Effects of Tirzepatide, a Dual GIP and GLP-1 Receptor Agonist, on Blood Pressure, Cardiac Function, and Sympathetic Nervous System in Stroke-Prone Spontaneously Hypertensive Rats. Hypertension Research. 2026;49(6):1924-1938. doi:10.1038/s41440-026-02632-6

8. Ala M, Moheb Aleaba M. The Blood Pressure-Lowering Property of Subcutaneous Semaglutide: A Systematic Review, Meta-Analysis, and Meta-Regression. Journal of Endocrinological Investigation. 2025;48(2):283-294. doi:10.1007/s40618-024-02459-3

9. Aronne LJ, Horn DB, le Roux CW, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. The New England Journal of Medicine. 2025;393(1):26-36. doi:10.1056/NEJMoa2416394

10. Mozaffarian D, Agarwal M, Aggarwal M, et al. Nutritional Priorities to Support GLP-1 Therapy for Obesity. The American Journal of Clinical Nutrition. 2025;122(1):344-367. doi:10.1016/j.ajcnut.2025.04.023

11. Theoharides TC, Twahir A, Kempuraj D. Mast Cells in the Autonomic Nervous System and Potential Role in Disorders With Dysautonomia and Neuroinflammation. Annals of Allergy, Asthma & Immunology. 2024;132(4):440-454. doi:10.1016/j.anai.2023.10.032